SARS-1: Serine-tRNA Ligase, A Key Enzyme in Protein Synthesis

Target Name: SARS1

NCBI ID: G6301

SARS1

SARS-1: Serine-tRNA Ligase, A Key Enzyme in Protein Synthesis

SARS-1 (Serine-tRNA ligase, cytoplasmic (isoform a)) is a protein that plays a crucial role in the regulation of protein synthesis in the cytoplasm of eukaryotic cells. It is a key enzyme in the transfer of serine tRNA from the cytoplasm to the ribosome during the process of translation. SARS-1 is a cytoplasmic protein, which means that it is located within the cytoplasm of the cell, and it is aISOform銆?

SARS-1 is a transmembrane protein that consists of a catalytic active site and a C-terminal region that includes a putative transmembrane glycoprotein (TMP) domain. The TMP domain is a protein that is often found in enzymes that transfer small molecules across cell membranes, and it is thought to be involved in the transfer of tRNA across the cytoplasmic membrane.

SARS-1 is expressed in most eukaryotic cells and is involved in the regulation of protein synthesis in the cytoplasm. It is highly conserved across different species, with only minor differences in its sequence and structure.

SARS-1 has been shown to play a role in the development and progression of various diseases, including SARS-CoV-2, a virus that causes COVID-19. Studies have shown that SARS-1 is overexpressed in the brains of COVID-19 patients and that it is involved in the regulation of the immune response.

SARS-1 has also been shown to be a potential drug target in the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. One approach to targeting SARS-1 is to use small molecules that can inhibit its activity, such as inhibitors of the TMP domain.

Another approach to targeting SARS-1 is to use antibodies that can specifically recognize and target the protein. This approach has been used to study the regulation of protein synthesis in various cell types and has led to the development of new drugs that can be used to treat various diseases.

Overall, SARS-1 is a protein that plays a crucial role in the regulation of protein synthesis in the cytoplasm of eukaryotic cells. Its activity is involved in the transfer of serine tRNA from the cytoplasm to the ribosome during the process of translation. SARS-1 is a cytoplasmic protein that is expressed in most eukaryotic cells and is involved in the regulation of protein synthesis in the cytoplasm. It is a potential drug target for the treatment of various diseases and is the subject of ongoing research in the field of molecular biology.

Protein Name: Seryl-tRNA Synthetase 1

Functions: Catalyzes the attachment of serine to tRNA(Ser) in a two-step reaction: serine is first activated by ATP to form Ser-AMP and then transferred to the acceptor end of tRNA(Ser) (PubMed:22353712, PubMed:24095058, PubMed:9431993, PubMed:26433229, PubMed:28236339, PubMed:34570399, PubMed:36041817). Is probably also able to aminoacylate tRNA(Sec) with serine, to form the misacylated tRNA L-seryl-tRNA(Sec), which will be further converted into selenocysteinyl-tRNA(Sec) (PubMed:9431993, PubMed:26433229, PubMed:28236339, PubMed:34570399). In the nucleus, binds to the VEGFA core promoter and prevents MYC binding and transcriptional activation by MYC (PubMed:24940000). Recruits SIRT2 to the VEGFA promoter, promoting deacetylation of histone H4 at 'Lys-16' (H4K16). Thereby, inhibits the production of VEGFA and sprouting angiogenesis mediated by VEGFA (PubMed:19423848, PubMed:19423847, PubMed:24940000)

The "SARS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SARS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets